Suven Life Sciences Preferential Issue
Suven's monitoring agency report covers its Rs 857.64 Crore preferential warrant proceeds for the quarter ended September 2026. Shareholders approved reallocation of objects on August 25, 2026.
- Value
- ₹857.6 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Suven's monitoring agency report covers its Rs 857.64 Crore preferential warrant proceeds for the quarter ended September 2026. Shareholders approved reallocation of objects on August 25, 2026.
Suven Life Sciences Ltd reported revenue from operations of ₹1.2 Cr (+33.3% YoY) and a net loss of ₹106.9 Cr for Q2 FY27.
Suven Life Sciences scheduled its board meeting for 5 November 2026 to approve Q1 and H1 FY27 unaudited results. The trading window closed from 1 October 2026 until 48 hours post-declaration.
Suven Life Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI regulations.